EATG » Scientific research

Scientific research

Discovery of key component of HIV yields new drug target

Scientists from the MRC Laboratory of Molecular Biology in Cambridge and University College London have discovered an essential feature of the HIV virus that it uses to infect cells whilst…

Genmab enters commercial license agreement with Gilead for DuoBody® technology

New commercial DuoBody technology platform collaboration with Gilead Genmab granted Gilead an exclusive license to create a bispecific antibody with the DuoBody technology and an option to obtain a second…

Can immunotherapy cure HIV?

A revolution in cancer care may offer clues to a cure or remission for HIV/AIDS HIV cure researchers and advocates met at Fred Hutchinson Cancer Research Center last week to…

Researchers develop method to study critical HIV protein

ALBUQUERQUE, N.M. – More than 36 million people worldwide, including 1.2 million in the U.S., are living with an HIV infection. Today’s anti-retroviral cocktails block how HIV replicates, matures and…

New antibody drug continues to show promise for treatment of HIV

Great strides have been made in recent years to develop treatment options for HIV, and the disease can now be controlled with anti-retroviral drugs. But a cure remains elusive and…

Study models how the immune system might evolve to conquer HIV

It has remained frustratingly difficult to develop a vaccine for HIV/AIDS, in part because the virus, once in our bodies, rapidly reproduces and evolves to escape being killed by the…

Study confirms simian ancestors of HIV can infect human cells

Humans susceptible to viral strains not found in population No one knows exactly how it happened. It may have entered through a cut or bite wound, the blood of a…

Comprehensive HIV vaccine project funded at $23 million by NIH

Texas Biomed establishes international team to develop multi-layered HIV defense strategy SAN ANTONIO (July 21, 2016) – To support a coordinated, innovative approach to the development of an AIDS vaccine,…

Neutrons key to discovering new HIV drugs?

An interview with Dr Matthew Blakeley Matthew Blakeley is a research scientist at the Institut Laue-Langevin in Grenoble, France. To read the interview, click here.

EHVA July 2016 Newsletter now out

EATG has been participating in the European HIV Vaccine Alliance as a consortium member responsible for communication and dissemination of progress, results and findings. With 37 million people living with…